Effect of Butorphanol on Colonoscopy for Patients With Postoperative Visceral Pain

Phase 4

Completed

• Conditions: Colonoscopy
• Interventions: Drug: Butorphanol Injection; Drug: Saline

• Registration Number: NCT04477733
• Lead Sponsor: Beijing Tiantan Hospital

Brief Summary

The total incidence of abdominal pain after colonoscopy is almost 50%. Butorphanol is a mixed opioid receptor agonist-antagonist, which has strong sedative and analgesic effects. This clinical study aims to explore the effectiveness and safety of butorphanol combined with propofol for colonoscopy to reduce postoperative visceral pain, and provide a basis for improving the quality of surgery and comfortable medical treatment for patients.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-10
• Study First Submitted QC: 2020-07-16
• Study First Posted: 2020-07-20
• Study Start: 2020-08-14
• Primary Completion: 2021-09-30
• Study Completion: 2021-09-30
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-18
• Last Update Posted: 2022-02-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 203

Inclusion Criteria

• ASA status I-11
• patients performing colonoscopy
• sign the informed consent

Exclusion Criteria

• BMI>30, pregnant
• diabetes
• depression
• patients dependent on opioids
• hypertension poorly controlled
• serious complications of important organs
• obvious abdominal pain before colonoscopy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Butorphanol group	Butorphanol Injection	-
control group	Saline	-

Primary Outcome Measures

Name	Time	Method
visceral pain	10 minutes after recovery	VAS score of visceral pain

Secondary Outcome Measures

Name	Time	Method
visceral pain at 20 and 30 minutes after recovery	20 and 30 minutes after recovery	VAS score of visceral pain

Trial Locations

Locations (1)

Beijing Tiantan Hospital; 🇨🇳 Beijing, China